A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function
Completed · Phase 1 · NCT05940402
Conditions: Renal Impairment
At a glance
- Research payments reported, 2025
- $296,896
- U.S. investigators named
- 5
- Sites paid
- 5
- Planned or actual enrollment
- 58
About the trial
- Sponsor
- AbbVie
- Tested
- Emraclidine (drug)
- Dates
- Started 2023-07-24; completion 2024-12-19
- Results posted
- Not yet
The primary purpose of this study is to assess the effect of renal impairment on the pharmacokinetics (PK) of emraclidine following administration of a single oral dose in participants with mild, moderate, and severe renal impairment relative to matched participants with normal renal function.
From ClinicalTrials.gov, last updated 2025-04-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $296,896 in research payments for this study in 2025 (22 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Joel M. Neutel, MD Legal Medicine (non-physician) · Tustin, CA
- Kwabena Ayesu, MD Internal Medicine · Orlando, FL
- Richard A. Preston, MD, MBA Clinical Pharmacology · Miami, FL
- Juan C. Rondon, MD Internal Medicine · Hollywood, FL
- William B. Smith, M.D. Specialist · New Orleans, LA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Clinical Research Services Inc $144,636
- Omega Research Orlando LLC $63,869
- Memorial Research Medical Clinic $57,600
- Alliance for Multispecialty Research LLC $27,791
- Erg Holding Company LLC $3,000
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.